Nyaradzai Sithole

Nyaradzai Sithole

Auto-generated profile, based on publicly available information

Nyaradzai Sithole

University of Cambridge

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2024 in Science Advances
Verified
Journal Article
Open access
BKBenjamin Krishna
Benjamin Krishna
ELEleanor Y. Lim
Eleanor Y. Lim
MMMarina Metaxaki
Marina Metaxaki
Sarah Elizabeth JacksonSarah Elizabeth Jackson
Sarah Elizabeth Jackson
LMLenette Mactavous
Lenette Mactavous
Mark R. WillsMark R. Wills
Mark R. Wills
After acute infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a proportion of patients experience persistent symptoms beyond 12 weeks, termed Long Covid. Understanding the mechanisms that cause this debilitating disease and identifying biomarkers for diagnostic, therapeutic, and monitoring purposes are urgently required. We detected persistently high levels of interferon-γ (IFN-γ) from peripheral blood mononuclear cells of patients with Long Covid using highly sensitive FluoroSpot assays. This IFN-γ release was seen in the absence of ex vivo peptide stimulation and remains persistently elevated in patients with Long Covid, unlike the resolution seen in patients recovering from acute SARS-CoV-2 infection. The IFN-γ release was CD8 + T cell–mediated and dependent on antigen presentation by CD14 + cells. Longitudinal follow-up of our study cohort showed that symptom improvement and resolution correlated with a decrease in IFN-γ production to baseline levels. Our study highlights a potential mechanism underlying Long Covid, enabling the search for biomarkers and therapeutics in patients with Long Covid.

1 August 2020 in Cell Reports Medicine
Verified
Journal Article
Open access
DCDami A. Collier
Dami A. Collier
SASonny M. Assennato
Sonny M. Assennato
BWBen Warne
Ben Warne
NSNyarie Sithole
Nyarie Sithole
KSKatherine Sharrocks
Katherine Sharrocks
IVIsabel Vicente
Isabel Vicente
There is an urgent need for rapid SARS-CoV-2 testing in hospitals to limit nosocomial spread. We report an evaluation of point of care (POC) nucleic acid amplification testing (NAAT) in 149 participants with parallel combined nasal and throat swabbing for POC versus standard lab RT-PCR testing. Median time to result is 2.6 (IQR 2.3–4.8) versus 26.4 h (IQR 21.4–31.4, p < 0.001), with 32 (21.5%) positive and 117 (78.5%) negative. Cohen’s κ correlation between tests is 0.96 (95% CI 0.91–1.00). When comparing nearly 1,000 tests pre- and post-implementation, the median time to definitive bed placement from admission is 23.4 (8.6-41.9) versus 17.1 h (9.0–28.8), p = 0.02. Mean length of stay on COVID-19 “holding” wards is 58.5 versus 29.9 h (p < 0.001). POC testing increases isolation room availability, avoids bed closures, allows discharge to care homes, and expedites access to hospital procedures. POC testing could mitigate the impact of COVID-19 on hospital systems.

11 July 2023 in British Medical Bulletin
Verified
Journal Article
Open access
PDF file
BKBenjamin Krishna
Benjamin Krishna
Mark R. WillsMark R. Wills
Mark R. Wills
NSNyaradzai Sithole
Nyaradzai Sithole
Introduction: Long COVID is a chronic condition that follows after acute COVID-19 and is characterized by a wide range of persistent, cyclic symptoms.Sources of data: PubMed search for publications featuring ‘Long COVID’ or ‘post-acute sequelae of COVID-19’.Areas of agreement: Long COVID occurs frequently post-acute COVID-19, with a majority of people experiencing at least one symptom (such as cough, fatigue, myalgia, anosmia and dyspnoea) 4 weeks after infection.Areas of controversy: The specific symptoms and the minimum duration of symptoms required to be defined as Long COVID.Growing points: There is a consistent reduction in Long COVID incidence amongst vaccinated individuals, although the extent of this effect remains unclear.Areas timely for developing research: There is an urgent need to understand the causes of Long COVID, especially extreme fatigue more than 6 months after infection. We must understand who is at risk and whether reinfections similarly risk Long COVID.

27 June 2022 in EBioMedicine
Verified
Journal Article
Open access
BKBenjamin A. Krishna
Benjamin A. Krishna
ELEleanor Y. Lim
Eleanor Y. Lim
LMLenette Mactavous
Lenette Mactavous
PLPaul A. Lyons
Paul A. Lyons
RDRainer Doffinger
Rainer Doffinger
NSNyaradzai Sithole
Nyaradzai Sithole
There is currently no consensus on the diagnosis, definition, symptoms, or duration of COVID-19 illness. The diagnostic complexity of Long COVID is compounded in many patients who were or might have been infected with SARS-CoV-2 but not tested during the acute illness and/or are SARS-CoV-2 antibody negative. Given the diagnostic conundrum of Long COVID, we set out to investigate SARS-CoV-2-specific T cell responses in patients with confirmed SARS-CoV-2 infection and/or Long COVID from a cohort of mostly non-hospitalised patients. We discovered that IL-2 release (but not IFN-γ release) from T cells in response to SARS-CoV-2 peptides is both sensitive (75% +/−13%) and specific (88%+/−7%) for previous SARS-CoV-2 infection >6 months after a positive PCR test. We identified that 42–53% of patients with Long COVID, but without detectable SARS-CoV-2 antibodies, nonetheless have detectable SARS-CoV-2 specific T cell responses. Our study reveals evidence (detectable T cell mediated IL-2 release) of previous SARS-CoV-2 infection in seronegative patients with Long COVID. This work was funded by the Addenbrooke's Charitable Trust (900276 to NS), NIHR award (G112259 to NS) and supported by the NIHR Cambridge Biomedical Research Centre. NJM is supported by the MRC (TSF MR/T032413/1) and NHSBT (WPA15-02). PJL is supported by the Wellcome Trust (PRF 210688/Z/18/Z, 084957/Z/08/Z), a Medical Research Council research grant MR/V011561/1 and the United Kingdom Research and a Innovation COVID Immunology Consortium grant (MR/V028448/1).

1 August 2022 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
BKBenjamin Krishna
Benjamin Krishna
MMMarina Metaxaki
Marina Metaxaki
MWMark R Wills
Mark R Wills
NSNyaradzai Sithole
Nyaradzai Sithole
Long coronavirus disease (COVID [LC]) constitutes a potential health emergency as millions of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections lead to chronic symptoms. We must understand whether vaccines reduce LC because this has major implications for health policy. We report a 79% reduction in LC referrals correlating with vaccination in the United Kingdom.

2 June 2020 in medRxiv
Verified
Preprint
Open access
PDF file
DCDami Aderonke Collier
Dami Aderonke Collier
SASonny M. Assennato
Sonny M. Assennato
BWBen Warne
Ben Warne
NSNyarie Sithole
Nyarie Sithole
KSKatherine Sharrocks
Katherine Sharrocks
RGRavindra Gupta
Ravindra Gupta
Background: There is urgent need for safe and efficient triage protocols for hospitalized COVID-19 suspects to appropriate isolation wards. A major barrier to timely discharge of patients from the emergency room and hospital is the turnaround time for many SARS-CoV-2 nucleic acid tests. We validated a point of care nucleic acid amplification based platform SAMBA II for diagnosis of COVID-19 and performed an implementation study to assess its impact on patient disposition at a major academic hospital. Methods: We prospectively recruited COVID-19 suspects admitted to hospital ( NCT04326387 ). In an initial pilot phase, individuals were tested using a nasal/throat swab with the SAMBA II SARS-CoV-2 rapid diagnostic platform in parallel with a combined nasal/throat swab for standard central laboratory RT-PCR testing. In the second implementation phase, we examined the utility of adding the SAMBA platform to routine care. In the pilot phase, we measured concordance and assay validity using the central laboratory as the reference standard and assessed assay turnaround time. In the implementation phase, we assessed 1) time to definitive bed placement from admission, 2) time spent on COVID-19 holding wards, 3) proportion of patients in isolation versus COVID negative areas following a test, comparing the implementation phase with the 10 days prior to implementation. Results: In phase I, 149 participants were included in the pilot. By central laboratory RT-PCR testing, 32 (21.5%) tested positive and 117 (78.5%). Sensitivity and specificity of the SAMBA assay compared to RT-PCR lab test were 96.9% (95% CI 0.838-0.999) and 99.1% (0.953-0.999), respectively. Median time to result was 2.6 hours (IQR 2.3 to 4.8) for SAMBA II SARS-CoV-2 test and 26.4 hours (IQR 21.4 to 31.4) for the standard lab RT-PCR test (p<0.001). In the first 10 days of the SAMBA implementation phase, we conducted 992 tests, with the majority (59.8%) used for hospital admission, and the remainder for pre-operative screening (11.3%), discharge planning (10%), in-hospital screening of new symptoms (9.7%). Comparing the pre-implementation (n=599) with the implementation phase, median time to definitive bed placement from admission was reduced from 23.4 hours (8.6-41.9) to 17.1 hours (9.0-28.8), P =0.02 in Cox analysis, adjusted for age, sex, comorbidities and clinical severity at presentation. Mean length of stay on a COVID-19 ‘holding’ ward decreased from 58.5 hours to 29.9 hours ( P <0.001). Use of single occupancy rooms amongst those tested fell from 30.8% before to 21.2% ( P =0.03) and 11 hospital bay closures (on average 6 beds each) were avoided after implementation of the POC assay. Conclusions: The SAMBA II SARS-CoV-2 rapid assay performed well compared to a centralized laboratory RT-PCR platform and demonstrated shorter time to result both in trial and real-world settings. It was also associated with faster time to definitive bed placement from the emergency room, greater availability of isolation rooms, avoidance of hospital bay closures, and greater movement of patients to COVID negative open “green” category wards. Rapid testing in hospitals has the potential to transform ability to deal with the COVID-19 epidemic.